Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Somatostatin × Endocrine × Clear all

Phase

Phase 2 2 Phase 4 1 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 2 Fluorouracil 2 Everolimus 2 Al18F-NOTA-octreotide 2 trametinib 1 toripalimab 1 fosbretabulin 1 fluorocholine 1 dabrafenib 1 combretastatin 1 cobimetinib 1 anlotinib 1 Water 1 Vemurafenib 1 Testosterone 1 Temozolomide 1 Somatostatin 1 Sodium Iodide 1 Sodium Chloride 1 Sirolimus 1 Radiotherapy 1 Radiofrequency Ablation 1 Positron Emission Tomography Computed Tomography 1 Paclitaxel 1 PE regimen 1 Oxaliplatin 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Injections 1 Erythromycin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06855095 2025-03-03

ATSA

The Netherlands Cancer Institute

Phase 2/3 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡